MING LIN: Open Payments
NPI 1912144288 · NEW YORK, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$389 in 16 payments from 7 companies in 2025. Trend: 2023 $689 · 2024 $908 · 2025 $389
Food & beverage: $389
| Company | Payments | Amount |
|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | 5 | $140 |
| BridgeBio Pharma, Inc. | 2 | $48 |
| ABBVIE INC. | 2 | $46 |
| AstraZeneca Pharmaceuticals LP | 2 | $45 |
| RECORDATI_RARE_DISEASES_INC. | 2 | $40 |
| E.R. Squibb & Sons, L.L.C. | 2 | $40 |
| Mallinckrodt Hospital Products Inc. | 1 | $31 |
Products named: JARDIANCE, Attruby, AVYCAZ, LOKELMA, ISTURISA, TERLIVAZ, ELIQUIS, CAMZYOS.
Industry payments across NY — which companies pay providers there.
